



Oriola's sale of Svensk dos AB to Apotekstjänst Sverige AB proceeds – sale expected to be completed in Q2 2025

Oriola Corporation Investor news 7 March 2025 at 1:00 p.m. EET

Oriola's sale of Svensk dos AB to Apotekstjänst Sverige AB proceeds – sale expected to be completed in Q2 2025

The Swedish Patent and Market Court of Appeal (Patent- och marknadsöverdomstolen) has approved Apotekstjänst Sverige AB's appeal regarding the sale of Svensk dos AB. Consequently, Oriola and Apotekstjänst Sverige will continue the sales process, which is expected to be completed in Q2 2025.

"We are very pleased with today's positive decision, which allows us to proceed with the sale of Svensk dos AB to Apotekstjänst Sverige AB. The sales process has been long, but the final outcome is the right one and will provide continuity to Svensk dos and the patients it serves," comments Oriola's CEO Katarina Gabrielson.

On 13 October 2023, Oriola announced the sale of all shares in Svensk dos AB to Apotekstjänst Sverige AB due to the tender market structure and dynamics. In April 2024, the Swedish Competition Authority (Konkurrensverket) prohibited the sale. Apotekstjänst Sverige AB's appeal to the Swedish Patent and Market Court (Patent- och marknadsdomstolen) was rejected in November 2024. Apotekstjänst Sverige AB decided to pursue the appeal to Swedish Patent and Market Court of Appeal (Patent- och marknadsöverdomstolen), which today approved the appeal and thereby the prohibition by the Swedish Competition Authority has been repealed.

Oriola Corporation

Further information:

Petter Sandström
General Counsel
tel. +358 10 429 5761
e-mail: petter.sandstrom@oriola.com

Distribution:

Nasdaq Helsinki Ltd.
Key media